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About 2.1 million new diagnosed breast cancer cases among women were estimated for 2018. 
Triple negative breast cancer (TNBC), characterized by the absence of hormone receptors 
(estrogen and progesterone), lack of expression of epidermal growth factor receptor-2 and poor 
prognosis, represents 10-20% of all breast cancers. Hence, the identification of novel 
biomarkers for this type of breast cancer is highly relevant for an early diagnosis. Additionally, 
TNBC peptide ligands can be used to design powerful drug delivery systems that specifically 
target this type of breast cancer. Therefore, the following study aimed to select and characterize 
novel peptides for a triple negative breast cancer murine mammary carcinoma cell line– 4T1. 
Using phage display, 7 and 12 amino acid random peptide libraries were screened against the 
4T1 cell line. A total of four rounds, plus a counter-selection round using the 3T3 murine 
fibroblast cell line, was performed. The enriched selective peptides were characterized and their 
binding capacity towards 4T1 tissue samples was confirmed by immunofluorescence and flow 
cytometry analysis. The selected peptides (4T1pep1 – CPTASNTSC and 4T1pep2—
EVQSSKFPAHVS) were enriched over few rounds of selection and exhibited specific binding 
to the 4T1 cell line. 
Exosomes derived from BJ cells were isolated by differential centrifugation and further 
characterized by nanoparticle tracking analysis, transmission electron microscopy (TEM), flow 
cytometry and western blot. Cell-derived exosomes were efficiently uptake by different TNBC 
cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-157 and Hs 578T). Moreover, in vivo 
circulation times and biodistribuition experiments were accomplished to assess performance. 
The ultimate goal is to develop multifunctional exosomes decorated with the previously selected 
peptides to achieve a drug delivery system with increased affinity/selectivity for triple negative 
breast cancer cells. Targeted exosomes have led to a completely new paradigm for the 
therapeutic delivery of drug molecules to specific targets, opening the door for new treatments 
of diseases caused by aberrant gene expression as cancer. 
